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1. 1. Object of the research
Polymorphism of the VDBP gene in young children.
A B S T R A C T
Object of the research: VDBP gene polymorphism.
Problem being addressed: the effect of existing polymorphic variants of the VDBP gene 
on the absorption of vitamin D in young children.
The main scientific results. At the beginning of the survey, vitamin D supplementation was 
performed in 50.0±9.1 % (15/30) of children. The concentration of 25 (OH) D in the serum 
of the subjects was 32.9 ng/ml (23.2–60.0). All patients with the GG rs 7041 genotype of the 
VDBP gene had a concentration of 25 (OH) D in the range of 20–100 ng/ml, which is statis-
tically more common than in children with the AA rs 4588 genotype (p=0.015), GT rs 7041 
genotype (p=0.047) and genotype TT rs 7041 (p=0.033). Patients with CA rs 4588 genotype – 
23.7 ng/ml (14.8-35.8) and GT rs 7041 – 28.1 ng/ml (17.1–49) had the lowest serum levels of 
25 (OH) D, the highest levels of 25 (OH) D – children with genotype AA rs 4588 – 122.6 ng/ml 
(23.2–124.1) and genotype TT rs 7041 – 78.6 ng/ml (23.2 –124.1). Carriers of the AA rs 4588 
genotype were more likely than patients with the GG rs 7041 genotype to show dangerously 
high levels of 25 (OH) D (p=0.069). Patients with the AA rs 4588 genotype had lower alkaline 
phosphatase levels compared to the GT rs 7041 and CC rs 4588 genotypes – 185.0 U/l (147.0–
212.0) versus 259.5 U/l (207.0–334.5), p=0.021 and against 251.0 U/l (222.0–346.0), p=0.016.
Area of practical application of research results: The results of the study can be used by 
working groups to make recommendations for the prevention and treatment of vitamin D 
deficiency and in the practice of health care facilities.
Innovative technological product: association between allelic variants of the VDBP gene 
and vitamin D status in young children.
Scope of application of innovative technological product: pediatrics, medical genetics.
Conclusions. Genetic variants of VDBP may affect the absorption of vitamin D and cause 
variability in 25 (OH) D levels, which complicates the development of uniform recommen-
dations for optimal prophylactic doses of vitamin D and necessitates additional research. 
The highest levels of 25 (OH) D were recorded in children with genotypes AA rs 4588 
and TT rs 7041 of the VDBP gene, which showed high absorption when taking vitamin D 
supplements at a dose of 500 IU/d and even excessive concentrations of 25 (OH) D with 
long-term supplementation in higher dose.








































































































































© The Author(s) 2020. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0).
52
No. 6 (71), 2020ScienceRise  ISSN 2313-8416
1. 2. Description of the problem
Vitamin D-binding protein (VDBP, vitamin D-binding protein, GS-globulin), which was 
identified in 1959, is one of the most common whey proteins and provides transport of about 90 % 
of circulating metabolites of vitamin D [1, 2] located in chromosome 4q11-q13 and consists of 
13 exons encoding 474 amino acid sequences [3]. VDBP is one of the main genes in which muta-
tions can affect the concentration of 25 (OH) D [4–6]. This is due to the fact that most vitamin D 
circulates in the blood in combination with GC (VDBP), which is present in plasma, cerebrospinal 
fluid, and in the process of metabolism is associated with various forms of vitamin D [7]. There 
are two known single nucleotide polymorphisms (SNPs) in exon 11 of the VDBP gene: rs 4588 and 
rs 7041 [8]. At present, the study of the relationship between the concentration of 25 (OH) D in 
serum and allelic variants of SNP rs 4588, rs 7041 of the VDBP gene continues. 
1. 3. Suggested way to solve the problem
There is thought that because the concentration of 25 (OH) D and the response to vitamin D 
supplementation are individual, the optimal dose of cholecalciferol for young children may also 
depend on genotype [4, 9, 10].
Analysis of the results of most recent studies on the effectiveness of vitamin D supplementa-
tion according to VDBP polymorphism indicates that individuals with genetic risk factors require 
higher doses of vitamin D [4, 8].
Today, the discussion on determining the optimal prophylactic doses of vitamin D, includ-
ing taking into account the different responses of individuals to supplementation, continues to 
study the factors that may affect the absorption of vitamin D, including genetic.
Despite numerous studies in this area, there is a lack of data that would apply to young chil-
dren. There are also insufficient data on the prevalence of different allelic variants of the VDBP 
gene among the population of Ukraine.
The aim of the research: to study the association between existing allelic variants of the 
VDBP gene and vitamin D status in young children. 
2. Materials and methods
The study was carried out on the basis of Communal non-profit enterprise “Kyiv City Chil-
dren’s Clinical Hospital No. 1” in 2017–2018 after receiving the opinion of the Commission on 
Bioethics at the National Medical Academy named after P. L. Shupyk and at the medical institution 
where the study was conducted. The study was conducted in accordance with the ethical principles 
of medical research conducted on people, which were adopted by the Declaration of Helsinki in 
2008. The protocol of the study was agreed for all participants.
Thirty children (continuous sample) aged from 4 months to 3 years were included in the 
survey. After providing detailed information about the study and obtaining prior consent to par-
ticipate in it, the children’s parents were surveyed using a specially designed questionnaire, which 
identified risk factors for vitamin D deficiency. 
According to the inclusion/exclusion criteria, the study did not include patients with  man-
ifest signs of rickets, children born prematurely, with intrauterine growth retardation, devel-
opmental defects, signs of immunosuppressive conditions, contraindications to vitamin D, and 
children whose parents did not provide written consent for further participation of children in 
the study.
In the second stage, all children were tested for levels of 25 (OH) D, total calcium and 
ionized, inorganic phosphorus, alkaline phosphatase, serum Ig A and total Ig E levels (labora-
tory LLC “New Diagnostics”, license AB 539668 from 22.04.10, Certificate of registration 
No. 12651020000001838 from 20.10.04) and molecular genetic study of polymorphic variants of 
the VDBP gene (rs 4588 and rs 7041) (SI “Reference Center for Molecular Diagnostics of the Min-
istry of Health of Ukraine”). 
Determination of serum level 25 (OH) D was performed by electrochemiluminescence 
method on the Elecsys 2010 analyzer (RocheDiagnostics, Germany) using Cobas test systems.
Peripheral blood for molecular genetic testing was collected in 3 ml vacuum Monovette 
with potassium salt of ethylenediaminetetraacetic acid as an anticoagulant (Vacutest, Italy) and 
frozen at –20 ºC. Transportation to the laboratory was performed in a thermobag with refrigerants. 
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A commercial DNA-sorb-B nucleic acid extraction kit (AmpliSens) was used to isolate genomic 
deoxyribonucleic acid.
Molecular genetic study of polymorphic variants of the VDBP gene (rs 4588 and rs 7041) 
was performed using modified protocols by PCR followed by analysis of RFLP.
The amplification reaction was performed in an amplifier “FlexCyclerBU” (AnalyticJena, 
Germany). Specific fragments were amplified using primers manufactured by Metabion (Germa-
ny) and a commercial PCR kit Master Mix PCR (“NEOGEN”, Ukraine). The amplification prod-
ucts of deoxyribonucleic acid fragments (amplicons) were subjected to hydrolytic cleavage by re-
striction endonucleases StyI (rs 4588) and HaeIII (rs7041) (“ThermoScientific”, USA), respectively. 
Restriction was performed in a TDB-120 microthermostat (“Biosan”, Latvia) at 37 °C for 12 hours 
and stopped at 65 °C for 20 minutes for rs 4588 polymorphism and 80 °C for rs 7041. The state of 
the restriction fragments was analyzed in a 3 % agarose gel (agarose from “Cleaver Scientific”, 
UK) with the addition of ethidium bromide using a transilluminator manufactured by “Cleaver 
Scientific”, UK (Fig. 1, 2).
Fig. 1. Electrophoregram of the distribution of restriction fragments of the rs 4588 polymorphism 
of the VDBP gene: sample 1 – molecular weight marker; samples 2–3, 5–13, 19 – CC genotype; 
samples 4, 14–18 – CA genotype
Fig. 2. Electrophoregram of the distribution of restriction fragments of the rs 7041 polymorphism 
of the VDBP gene: sample 1 – molecular weight marker; samples 2–3, 6–8, 10–12 – genotype 
GG; samples 4, 9, 13–19 – genotype GT, sample 5 – genotype TT
The frequency distribution of alleles and genotypes rs 4588, rs 7041 of the VDBP gene 
in the examined children was compared with the data presented in the global database SNPedia 
(1000 genomes) [11].
The results of the study were statistically processed using standardized tools Microsoft Ex-
cel 2010 and the application package Statistica 10.0. The nature of the distribution was determined 
by the Shapiro-Wilk test. Qualitative indicators in the article are given in the form of absolute val-
ues and their errors (M±m), of which relative (%) are calculated, in the format n/N, where n is the 
number of cases, and N is the size of the corresponding group. Given the asymmetric nature of the 
distribution, descriptive statistics for quantitative indicators are presented in the form of median 
and interquartile range – Me (Q1–Q3), where Me is the median, Q1; Q3 – 25 and 75 quartiles. Com-
parison of qualitative indicators was performed using Pearson’s χ2 criterion. Quantitative indicators 
were evaluated according to the Mann-Whitney U criterion - for independent groups and the Wil-
coxon criterion – for dependent groups. P<0.05 was taken as the critical level of significance when 
testing statistical hypotheses.
3. Research results
Among the patients included in the study, there were 36.7±8.8 % (11/30) of boys and 
63.3±8.8 % (19/30) of girls (p=0.071). Most children were in the first (36.7±8.8 %) (11/30) and sec-
ond year of life (43.3±9.0 %) (13/30), 20.0±7.3 % (6/30) children were aged 2 to 3 years.
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It was found that at the beginning of the survey vitamin D supplementation was performed 
in 50.0±9.1 % (15/30) of children. Among children receiving supplementation, in 46.7±12.9 % (7/15) 
parents preferred an oil solution of cholecalciferol, and in 53.3±12.9 % (8/15) – an aqueous solution, 
with a daily dose vitamin D was 500 IU/d in 40.0±12.6 % (6/15), 1000 IU/d – in 60.0±12.6 % (9/15) 
of children. No child received cholecalciferol at a dose greater than 1000 IU/d. Children under 
1 year of age received supplementation in 90.9±8.7 % (10/11) of cases. In the second year of life, 
38.5±13.5 % (5/13) of the subjects received vitamin D, and in the third year, supplementation was 
not performed on any child (0/4).
The median concentration of 25 (OH) in the serum of the examined children was at the level 
of 32.9 ng/ml (23.2–60.0) with individual fluctuations from 6.6 ng/ml to 233.8 ng/ml. The maxi-
mum level of 25 (OH) was determined in a 4-month-old girl who had no risk factors for vitamin D 
deficiency, was exclusively breastfed, and regularly received an aqueous solution of cholecalciferol 
at a dose of 1000 IU from 1 month of age until enrolment. The status of vitamin D in patients 
included in the study was assessed according to official documents and classifications of leading 
international communities: Global consensus recommendations on prevention and management 
of nutritional rickets, American Academy of Pediatrics, Pediatric Endocrine Society, Canadian 
Pediatric Society [12–15].
As a result of molecular genetic study of polymorphic variants of the VDBP gene, it was found 
that the frequency of distribution of genotypes and alleles by polymorphism rs 4588 in the study group 
corresponded to Hardy-Weinberg law and did not differ significantly from world data (p>0.05). How-
ever, compared to the international database, the TT rs 7041 (p=0.005) and T allele rs 7041 (p=0.000) 
genotypes were significantly more common in the examined children and the GG rs 7041 (p=0.003) and 
G genotypes were significantly less common allele rs 7041 (p=0.000) (Table 1).
Table 1
Frequency distribution of alleles and genotypes rs 4588, rs 7041 of the VDBP gene in young children compared 
to the international database
Polymorphism Genotypes
Group of examined children 1000 genomes
P
n=30 M±m (%) n=503 M±m (%)
rs 4588
CC 15 50.0±9.1 165 32.8±2.1 0.083
CA 10 33.3±8.6 257 51.1±2.2 0.089
AA 5 16.7±6.8 81 16.1±1.6 0.862
C allele 40 66.7±6.1 587 58.3±2.2 0.256
A allele 20 33.3±6.1 419 41.7±2.2 0.256
rs 7041
GG 8 26.7±8.1 281 55.9±2.2 0.003
GT 16 53.3±9.1 195 38.8±2.2 0.164
TT 6 20.0±7.3 27 5.4±1.0 0.005
G allele 32 53.3±6.4 757 75.2±1.9 0.000
T allele 28 46.7±6.4 249 24.8±1.9 0.000
It was found that there was a tendency to a higher frequency of the T allele rs 7041 in boys 
(p=0.052). There was no gender difference in the frequency distribution of other alleles and geno-
types by polymorphisms rs 4588, rs 7041 of the VDBP gene (p>0.05).
Patients with CA rs 4588 genotypes – 23.7 ng/ml (14.8–35.8)  Dand GT genotype rs 7041 – 
28.1 ng/ml (17.1–49) had the lowest serum levels of 25 (OH), and the highest levels were recorded in 
children with genotype AA rs 4588 – 122.6 ng/ml (23.2–124.1) and genotype TT rs 7041–78.6 ng/ml 
(23.2–124.1) (Fig. 3).
In total, the examined children had 5 combinations of genotypes out of 9 possible. It was 
found that the genotype AA rs 4588 in 100 % of cases was combined with the genotype TT rs 7041, 
and the genotype CA rs 4588 in 100 % of cases was combined with the genotype GT rs 7041. The 
study did not reveal the following combinations of genotypes by polymorphisms rs 4588 and rs 
7041 VDBP gene: CA/GG, CA/TT, AA/GG, AA/GT.
In the examined young children with a combination of CA/GT genotypes, the lowest levels 
of 25 (OH) D were recorded – 23.7 ng/ml (14.8–35.8), with 60.0±15.5 % (6/10) children with this 
combination of genotypes had a low level of vitamin D (<30 ng/ml). Among children with this 
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combination of genotypes, only one child (10.0±9.5 %) (1/10) never received vitamin D at all (level 
25 (OH) D – 30.3 ng/ml); 40.0±15.5 % (4/10) received cholecalciferol at the time of the survey, 
among them 2 children underwent supplementation at a dose of 1000 IU/d (at a dose of 1000 IU/d – 
level 25 (OH) D 23.41 ng/ml and 51.37 ng/ml; at a dose of 500 IU/d – 19.49 ng/ml and 157.1 ng/ml). 
 Median 
 25%-75% 
 Non-Outlier Range 
 Outliers

























rs4588  rs 7041 
Fig. 3. The concentration of 25 (OH) D in young children depending on the polymorphisms rs 
4588 and rs 7041 of the VDBP gene
In the examined young children with a combination of CA/GT genotypes, the lowest levels 
of 25 (OH) D were recorded – 23.7 ng/ml (14.8–35.8), with 60.0±15.5 % (6/10) children with this 
combination of genotypes had a low level of vitamin D (<30 ng/ml). Among children with this 
combination of genotypes, only one child (10.0±9.5 %) (1/10) never received vitamin D at all (level 
25 (OH) D – 30.3 ng/ml); 40.0±15.5 % (4/10) received cholecalciferol at the time of the survey, 
among them 2 children underwent supplementation at a dose of 1000 IU/d (at a dose of 1000 IU/d – 
level 25 (OH) D 23.41 ng/ml and 51.37 ng/ml; at a dose of 500 IU/d – 19.49 ng/ml and 157.1 ng/ml). 
The highest concentration was 25 (OH) D in children with a combination of AA/TT geno-
types – 122.6 ng/ml (23.2–124.1). The vast majority of carriers of this combination (60.0±21.9 %) 
(3/5) recorded a level that, according to the Global consensus recommendations on prevention and 
management of nutritional rickets, is toxic (>100 ng/ml). These were children of the first year of life 
who were exclusively breastfed, received an aqueous solution of vitamin D and had no concomitant 
pathology. Two of them received supplementation of cholecalciferol at a dose of 500 IU/d (level 
25 (OH) D was 122.6 ng/ml and 124.1 ng/ml, respectively), and one patient aged 4 months received 
vitamin D at a dose of 1000 IU/d, with supplementation lasting only 2 months (concentration of 
25 (OH) D at the time of the initial examination in this child was 215.9 ng/ml). Among the genes 
examined with this combination, two children were the exception – they had a concentration of 
this metabolite of vitamin D did not exceed 100 ng/ml: one child (33 months), supplementation was 
carried out only up to 12 months, and the other (9 months) – irregular taking the drug. 
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Level 25 (OH) D, which exceeded 150 ng/ml (153.3 ng/ml and 233.8 ng/ml), was recorded in 
two more patients who had a combination of genotypes CC/GT (33.3±19.2 %) (2/6). Both children 
were under 1 year of age and received supplementation at a dose of 1000 IU/d from 1 month of age 
until the initial examination.
The analysis of the level of vitamin D supply depending on the polymorphisms of the VDBP 
gene was performed. It was found that only carriers of genotypes CA rs 4588 and GT rs 7041 had 
severe vitamin D deficiency (<10 ng/ml), but no significant difference was obtained, which was 
probably due to insufficient sample size (Table 2).
Table 2
The level of vitamin D supply in young children depending on the polymorphism of the VDBP gene





Genotypes rs 4588 (%) Genotypes rs 7041 (%)
СС СA AA GG GT TT
Global consensus recommendations on prevention and management of nutritional rickets
<12 6.7±4.6 0 20.0±12.6 0 0 12.5±8.3 0
12–20 13.3±6.2 6.7±6.5 20.0±12.6 20.0±17.9 0 18.7±9.7 16.7±15.2
>20 80.0±7.3 93.3±6.5 60.0±15.5 80±17.9 100 68.8±11.6 83.3±15.2
>100 20.0±7.3 13.3±8.8 10.0±9.5 60.0±21.9# 0# 18.7±9.7 50.0±20.4
American Academy of Pediatrics
<20 20.0±7.3 6.7±6.5 40.0±15.5 20.0±17.9 0 31.3±11.6 16.7±15.2
20–30 23.3±7.7 26.7±11.4 20.0±12.6 20.0±17.9 37.5±17.1 18.7±9.7 16.7±15.2
>30 56.7±9.0 66.6±12.2 40.0±15.5 60.0±21.9 62.5±17.1 50.0±12.5 66.6±19.3
Pediatric Endocrine Society
<15 13.3±6.2 6.7±6.5 30.0±14.5 0 0 25.0±10.8 0
15–20 6.7±4.6 0 10.0±9.5 20.0±17.9 0 6.3±6.1 16.7±15.2
20–100 60.0±8.9 80±10.3 50.0±15.8 20.0±17.9* 100*/**/*** 50.0±12.5*** 33.3±19.2**
>150 13.3±6.2 6.7±6.5 10.0±9.5 20.0±17.9 0 18.7±9.7 16.7±15.2
Canadian Pediatric Society
<10 6.6±4.5 0 20.0±12.6 0 0 12.5±8.3 0
10–30 36.7±8.8 33.3±12.2 40.0±15.5 40.0±21.9 37.5±17.1 37.5±12.1 33.3±19.2
30–90 36.7±8.8 53.3±12.9 30.0±14.5 0 62.5±17.1 31.3±11.6 16.7±15.2
>200 6.6±4.5 6.7±6.5 0 20.0±17.9 0 6.3±6.1 16.7±15.2
Note: * – the probability of differences (p<0.05) between children with genotype GG rs 7041 and patients with genotype 
AA rs 4588; ** – probability of differences (p<0.05) between children with GG rs 7041 genotype and patients with TT rs 
7041 genotype; *** – probability of differences (p<0.05) between children with genotype GG rs 7041 and patients with 
genotype GT rs 7041; # – probability of differences (p<0.05) between children with genotype AA rs 4588 and patients 
with genotype GG rs 7041
All children with the GG rs 7041 genotype of the VDBP gene had a concentration of 25 
(OH) D in the range of 20–100 ng/ml, which is statistically more common than in children with 
the AA rs 4588 genotype (p=0.015), GT rs 7041 genotype=0.047) and the TT genotype rs 7041 
(p=0.033). At the time of inclusion in the study, 37.5±17.1 % (3/8) of these patients received vita-
min D at a dose of 1000 IU/d. Carriers of the AA rs 4588 genotype showed dangerously high levels 
of 25 (OH) D (p=0.069) more often than patients with the GG genotype rs 7041.
Analysis of other indicators of phosphorus–calcium metabolism depending on polymorphic 
variants of the VDBP gene showed that patients with the AA rs 4588 genotype had lower levels of 
alkaline phosphatase compared to children with the GT rs 7041 and CC rs 4588 genotypes – 185.0 
U/l (147.0–212.0) against 259.5 U/l (207.0–334.5), p=0.021 and against 251.0 U/l (222.0–346.0), 
p=0.016. This can be explained by significantly higher levels of 25 (OH) D in children with the AA 
rs 4588 genotype, compared with patients with the GT rs 7041 and CC rs 4588 genotypes.
4. Discussion of research results
Thus, a study examining the relationship between VDBP gene polymorphism and vita-
min D status in relatively healthy young children demonstrated the presence of different allelic 
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variants of this gene in the population. Subjects with AA rs 4588 and TT rs 7041 genotypes of the 
VDBP gene had the highest serum 25 (OH) D concentrations. Similar results were obtained in 2019 
by M. Mehramiz et al., who investigated the effect of genetic polymorphisms of the VDBP gene at 
the level of 25 (OH) D in 619 Iranian adolescent girls. Subjects received high doses of vitamin D 
(50,000 IU/week for 9 weeks). The results of the study showed that patients with the AA rs 4588 
genotype of the VDBP gene responded better to vitamin D intake than children with the GG rs 
7041 genotype [16].
At the same time, in a Greek study examining the association between serum 25 (OH) D 
levels and VDR Apal, VDBP rs 4588 and rs 7041 polymorphisms in 69 children with bronchial 
asthma, the TT rs 7041 genotype of the VDBP gene, in contrast, associated with lower levels of 25 
(OH) D in these patients [17].
Study limitations. Because the results of this study are limited by the small sample power, 
and different researchers point to conflicting data, further studies in larger cohorts are needed. 
The presence of different allelic variants of the VDBP gene may explain the different responses of 
individual subjects to vitamin D supplementation and indicate the need to correct existing stan-
dards for the prevention and treatment of rickets and other pathological conditions associated with 
vitamin D deficiency.
Prospects for further research. The study of the prevalence of different allelic variants 
of the VDBP gene will clarify the data obtained on their association with the status of vitamin D, 
individualize and optimize approaches to supplementation and treatment of pathological conditions 
associated with vitamin D deficiency.
6. Conclusions
1. Performed tests indicate the presence of polymorphic variants of the VDBP gene in children 
in Ukraine, which may affect the effectiveness of prevention of rickets by supplementation of vitamin D.
2. Compared with the international database, the TT rs 7041 genotype (p=0.005) and T 
allele rs 7041 genotype (p=0.000) were significantly more common in the examined children and 
the GG rs 7041 genotype (p=0.003) and G allele rs 7041 genotype (p=0.000) were significantly 
less common.
3. Optimal levels of 25 (OH) D in serum, regardless of the dose of supplements, were demon-
strated by all examined young children with genotype GG rs 7041 gene VDBP.
4. Low concentrations of 25 (OH) D were determined mainly in the examined children with 
genotypes CA rs 4588 and GT rs 7041 of the VDBP gene.
5. The highest levels of 25 (OH) D were recorded in children with genotypes AA rs 4588 and 
TT rs 7041 of the VDBP gene, which showed high absorption when taking vitamin D supplements 
at a dose of 500 IU/d and even excessive concentrations of 25 (OH) D with long-term use supple-
ments in a higher dose.
6. For final conclusions on the potential impact of VDBP gene polymorphism on the effec-
tiveness of prevention of vitamin D deficiency, it is necessary to conduct research on large cohorts 
of children and adults in Ukraine.
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